Tadekinig alfa
As of the edition of 20 October 2026, Tadekinig alfa is a drug: in active development; acts on IL18.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2017
- Kind
- Unknown
- Registered trials
- 4, 0 stopped early
- Disease areas
- Bones, joints and muscles; Immune system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IL18 | Interleukin-18 | Q14116 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 1 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 2 | 2 | 0 | 0 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| AB2 Bio | Lead sponsor of trials | 2015 to now |